• While traditional lenders remain reluctant to serve state-licensed cannabis industry prospects, REZYFi focuses on servicing the sector
• ResMac subsidiary expects to accumulate $285 million in retail origination and $250 million in wholesale origination in 2023
• The National Association of Realtors(R) reported one-third of surveyed agents experienced an increase in demand for warehouses, 28% in land demand, and 23% in demand for storefront property

REZYFi, a cannabis mortgage bank servicing the needs of both traditional and non-traditional consumers and businesses, is one of the first mortgage bankers of its kind in the United States, leveraging its position in a market where most traditional lenders remain diffident to serve the state-licensed cannabis industry. Through its two wholly owned subsidiaries – REZYFi Lending and ResMac Inc. – REZYFi is targeting licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners seeking a variety of real estate-related first and additional mortgage-based financing and project-specific financing. Through REZYFi Lending, the company is leveraging a wide network to offer multiple options, including 15- to 30-year fixed rate loans, FHA loans, VA loans, reverse mortgages, jumbo loans, and adjustable-rate mortgages. The company expects increased funding in marketing and loan agents to drive significant growth in origination over the next two years, which is supported by the planned launch of a high-margin cannabis division later in 2022. In operation for 13 years, ResMac Inc. has closed more than 20,000 loans for more than 15,000 clients and expects to accumulate $285 million in retail origination and $250 million in wholesale origination in 2023. ResMac is also targeting $600 million in origination through its mortgage correspondent operations during the same period. The company intends to harvest the database of customers within its mortgage servicing operations as an essential source for expanding the new alternative residential loan programs it will operate. In an April 2021 report titled Marijuana and Real Estate: A Budding Issue, the National Association of Realtors(R) (“NAR”) examines the impact that cannabis legalization has on the real estate industry. In states where prescription and recreational cannabis use is legal, more than one-third of the agents surveyed reported an increase in demand for warehouses, 28% observed increases in land demand, and 23% reported increases for storefront property (https://ibn.fm/0C3WE). REZYFi is demonstrating its corporate strengths within the market through experience, a network of independent brokers, and proprietary technology through both subsidiaries. The company is led by a seasoned management team with over 40 years of combined experience in the mortgage and lending industry, as well as experience in the cannabis and hemp marketplace. Over the past five years, REZYFi has developed an extensive network of independent mortgage-related brokers and licensed loan officers – with training that has already commenced for network members to familiarize them with the company’s new service offerings. Through its proprietary automated/machine learning technology, REZYFi shortens loan processing timeframes and increases efficiencies, allowing it to operate its legacy business at staffing levels meaningfully below its competition. For more information, visit the company’s website at www.REZYFi.com. NOTE TO INVESTORS: The latest news and updates relating to REZYFi are available in the company’s newsroom at https://ibn.fm/REZY

• US natural gas prices rose nearly 50% in July, EU benchmark power price hit ten times decade-long average
• Prices expected to remain volatile until at least 2023
• GeoSolar’s SmartGreen(R) systems help building owners achieve energy independence with photovoltaic (“PV”) solar systems and geothermal ground loops
• Additional SmartGreen(R) system customizations include tightening building envelope, insulation upgrades, LED lighting replacement, and EV charging infrastructure
• SEC recently qualified GeoSolar for Regulation A+ capital raise

Energy prices are skyrocketing, especially in Europe where the benchmark power price recently hit 1,000 euros (USD $990) per megawatt-hour – nearly ten times the decade-long average (https://ibn.fm/uXrTc). With no end in sight to the Ukraine conflict, Europeans are bracing for the worst following news that energy prices will remain “high and volatile” until at least 2023 (https://ibn.fm/8hNEF). Accordingly, US natural gas prices rose by nearly 50% in July, dashing any hopes consumers and businesses had for declining inflation (https://ibn.fm/5g4uZ). Some building owners, however, are largely insulated from the crisis by installing GeoSolar Technologies’ SmartGreen(R) residential and commercial energy systems that tap into the power of the sun and earth to dramatically lower or eliminate utility bills. Up to 84 million homes in the United States depend on obsolete fossil fuel-driven energy systems (https://ibn.fm/yQWPy). Not only does that leave homeowners vulnerable to price shocks similar to those seen today, but it also increases dependency on foreign powers, causes geopolitical conflict, and contributes to pollution that compromises the quality of human, animal, and plant life across the planet. GeoSolar is dedicated to advancing technology that addresses all those issues while giving building owners energy independence. The company’s SmartGreen(R) residential and commercial energy systems harness the sun’s power through photovoltaic (“PV”) solar systems that generate electricity year-round to power appliances and charge EVs. In addition, heating and cooling needs are met with geothermal ground loops that use the earth as a heat source or heat sink, depending on the building’s temperature requirements. Solar and geothermal systems are only part of the SmartGreen(R) equation. The system encompasses a total home energy makeover to increase efficiency, including tightening the building envelope, upgrading insulation, replacing windows, and installing LED lights. GeoSolar’s system can be optimized for any building size, type, or design, allowing owners to integrate SmartGreen(R) into new building developments or existing homes within weeks. GeoSolar is dedicated to achieving carbon-free living by 2035. With a successful track record of installations across Colorado, GeoSolar aims to market SmartGreen(R) to over one hundred million homes across the United States with 100% financing options, tax deductions, and utility incentives. The company was recently qualified by the U.S. Securities and Exchange Commission to conduct a Regulation A+ capital raise, and additionally plans to file for an OTCQB listing on the national OTC market with the trading symbol GSOL upon offering completion. For more information on GeoSolar’s Regulation A+ capital raise, please visit https://www.manhattanstreetcapital.com/geosolar-technologies-inc. For more information, visit the company’s website at www.GeoSolarPlus.com. NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST

• U.S.-based drug innovator CNS Pharmaceuticals is enrolling patients in a global clinic trial to evaluate the performance of the company’s lead drug candidate, Berubicin, in fighting glioblastomas
• Glioblastoma is an incurable brain cancer that is aggressive in its progression and recurrence, leaving most patients with a life expectancy of less than a year after diagnosis
• CNS’s efforts to fill an unmet medical need arise from promise shown during Berubicin’s initial development by another company over 15 years ago, which included a small-scale human safety trial that produced a patient with no detectable cancer and others that saw tumor shrinkage and stable disease
• The FDA has granted Berubicin Fast Track and Orphan Drug status and enrollment for the current potentially pivotal global Phase 2 clinical trial is taking place in the United States, France, Spain and Switzerland

An incurable brain cancer known as glioblastoma multiforme (“GBM”) has drawn the attention of researchers throughout the world as the medical science industry races to fill an unmet need for an effective treatment. While surgery is a standard procedure for removing cancerous GBM tumors, the tumors tend to regrow within a narrow margin of time because of the cancer’s capacity to infiltrate the surrounding tissues, preventing the surgeon from clearly identifying the boundaries between the tumor and the normal tissue. And because of the vital importance of the brain, overly aggressive tissue removal is out of the question. “So the tumor will come back again, and that sharply decreases the survival rate after treatment,” University of Wisconsin–Madison School of Pharmacy’s Pharmaceutical Sciences Division assistant professor Quanyin Hu stated in a report on the school’s work to develop a GB treatment for improving GBM survival rates in lab animals (https://ibn.fm/CRwdr). Biopharmaceutical innovator CNS Pharmaceuticals (NASDAQ: CNSP) is staking out its own position within the competitive field of research, having already progressed to human trials of the company’s novel GBM solution, known as Berubicin (or WP744). Berubicin is a patented doxorubicin (“Dox”) analog — an anthracycline chemotherapy agent novel in its ability to cross the blood-brain barrier to target tumors directly. Tested against Dox in cancer cells, Berubicin showed a greater capacity to destroy or damage the cancers. In models evaluating intracranial gliomas, Berubicin showed a greater capacity to prolong life than temozolomide, another standard of care in GBM (https://ibn.fm/QdfUa). Other anthracyclines have been limited in their ability to fight brain cancers by their inability to cross the blood-brain barrier, but Berubicin’s unique capacity potentially led to significant outcomes in its earliest safety trial conducted by the drug’s initial developer, Reata Pharmaceuticals. In that small-scale Phase I clinical trial in 2006, one of the two dozen evaluated patients emerged cancer-free and has remained so over the subsequent years up to today. Nearly half of the trial’s other patients experienced a statistically significant improvement in clinical benefit of stable disease or better (https://ibn.fm/mA0KA). For a trial participant patient to survive cancer-free for well over a decade is a remarkable outcome given the disease’s statistics — approximately 13,000 patients receive new GBM diagnosis each year in the United States and have an average survival time of less than a year after diagnosis. Only 10 percent or less survive to five years (https://ibn.fm/H3vyJ). CNS Pharmaceuticals’ ongoing development of Berubicin includes two dozen trial enrollment sites that are already open, with up to 54 planned at selected locations in the United States, Italy, France, Spain and Switzerland, the most recent approvals in Europe being granted in April with additional countries being considered. This global trial is comparing Berubicin responses to yet another GBM standard of care, Lomustine. By next summer, the company expects to have gathered enough data for an interim analysis (https://ibn.fm/l0Jf9). Berubicin has already been granted Fast Track and Orphan Drug designations by the U.S. Food and Drug Administration (“FDA”), which may further boost its development as the company reports its results. For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Correlate’s operations have been influenced by the United States’ push to achieve its 2050 carbon goals, along with the evolving ESG criteria which defines the standards by which companies should operate
• With more companies realizing the significance of having and implementing ESG goals, Correlate is looking at an opportunity to grow its customer numbers
• 76% of managers already implement ESG within their fixed income, up from 42% in 2021. Also, 74% of companies incorporate ESG in equities, up from 53% in 2021
• Correlate’s unique value proposition of affordability and potential profit of its ESG-related energy solutions differentiates the company from the rest in the industry, while offering an opportunity for both big and small enterprises to achieve their ESG goals

Correlate Infrastructure Partners (OTCQB: CIPI), a technology-enabled energy optimization and clean energy solutions provider for the United States commercial real estate industry has, since its inception, been committed to delivering a complete suite of proprietary clean energy assessment and fulfilment solutions for the market. This has been largely influenced by recognizing a significant opportunity in the market, coupled with the country’s push to achieve its stated 2050 carbon goals. Correlate’s operations have been further influenced by the evolving environmental, social, and governance (“ESG”) criteria, that define the responsibility standards by which a growing number of companies are being judged in the marketplace. ESG goals have helped to outline corporate policies associated with climate change, relationships with customers, suppliers, and the communities where it operates, along with their leadership and even shareholder rights. Most importantly, they have greatly influenced the push towards renewable sources of energy. As time progresses, more companies are realizing the significance of having and implementing ESG goals, and this is, in turn, presenting a unique opportunity for Correlate to grow its customer numbers. In a recent survey published by Reuters, it was noted that currently 76% of managers actively implement ESG within their fixed income, a significant rise from 42% back in 2021. In addition, the study noted that 74% of companies incorporate ESG in equities, up from 53% in 2021 (https://ibn.fm/jsrEr). This surge, the report noted, reflects managers’ improved ability to assess ESG signals in the asset class, along with investors’ eagerness to diversify beyond ESG equity funds. Companies have even projected that in the next 12 months, 40% of their portfolios will include ESG elements, up 13 percentage points from the 2021 survey. There are several ways through which companies can improve their ESG score. However, the main ones touch on energy efficiency, along with water usage, waste production, and CO2 emissions (https://ibn.fm/20xYq). This is where Correlate comes in. With commercial buildings consuming over 35% of generated electricity in the United States, and emitting too much carbon, there is an increasingly recognized need to shift to more renewable energy sources. With Correlate’s industry-leading energy solution and financing platform, the company is aiding in significantly reducing site-specific energy consumption, deploying clean energy generation and efficiency solutions that help companies achieve their ESG objectives. Already, Correlate has an opportunity pipeline of over $100 million in commercial projects, with over $20 million in awarded backlog. As more companies recognize the value of achieving ESG goals, Correlate can expect to grow its customer numbers and, consequently, its revenue as time progresses. The company’s unique value proposition, including the affordability and profit potential of its ESG-related energy solutions, differentiates Correlate from other players in the industry. It is also lowering the barrier of entry for even small organizations to adopt renewable energy solutions, allowing for the easy achievement of their set ESG goals. This reflects Correlate’s understanding of the market, and its commitment to creating value, not just for its customers but also its shareholders. For company information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• A 2017 study by McKinsey & Company showed that high performers tend to be 400% more productive than average ones.
• This outlook has shaped Flora Growth’s hiring strategy for 2022, with the appointment of several key individuals whose proven talents and productivity are seen as critical to the company’s goal of delivering the most compelling customer experiences, most recently with the appointment of Elshad Garayev as Flora’s Chief Financial Officer (“CFO”)
• Mr. Garayev’s appointment marks the latest addition to a growing list of leaders ready to elevate the company to another level of international performance

In a study conducted in 2017 by McKinsey & Company, it was established that high performers tend to be 400% more productive than average ones. The study, which involved over 600,000 researchers, athletes, politicians, and entertainers, also revealed that, in a business setting, the gap rises exponentially with a job’s complexity, sometimes by an astounding 800% (https://ibn.fm/SYsVD). The study’s objective was to highlight the importance of hiring the right people for the right job. It was also meant to show why having the right talent on the team can reduce the time it takes to complete tasks and how long it would take to achieve organizational objectives. Most notably, the study noted that for a business strategy involving cross-functional initiatives requiring three years to complete, if 20% of the average talent working became 400% more productive, it would take less than two years to complete. Conversely, if these individuals were 800% more productive, it would take less than one. These dynamics continue to shape the overall hiring approach and process for various organizations in different industries, and Flora Growth (NASDAQ: FLGC) is no exception. Since the beginning of the year, the company has been committed to looking for the best talent in the job market and devising ways to increase their productivity. Its management fully understands that doing so would not only lessen the time taken to achieve its short-term and long-term goals but also significantly cut down on its overall operational costs, thereby creating value for its shareholders. Flora Growth ushered in the new year with the appointment of Tim Leslie as chairman of its newly formed advisory board. It would later bring Derek Pedro, an industry-leading cannabis genetics and cultivation expert, on board as an advisor and named Vessel founder, James Choe as Chief Strategy Officer. In February 2022, Flora Growth announced the appointment of Jessie Casner as the company’s Chief Marketing Officer, and, in March, made two changes to its board. Then, in early June (https://ibn.fm/pxyLZ), Flora announced the appointment of Holly Bell as the new Vice President of Regulatory Affairs in a move that sought to position Flora to make “thoughtful, educated, and bold decisions regarding strategic distribution, cultivation and sales plans.” So far, all of Flora Growth’s appointments have been geared toward strengthening its human resources and moving the company closer to its objectives. Its latest appointment of Elshad Garayev is no different. Mr. Garayev was brought on board to serve as Flora’s Chief Financial Officer (“CFO”) effective on the business day following the date the company will file its mid-year financial results with the Securities and Exchange Commission. “I am very excited to join Flora and to become its Chief Financial Officer,” Garayev noted. “As one of the largest cultivators licensed by the government of Colombia, their robust portfolio of brands and the future of research in the space, Flora presents a truly amazing opportunity to lead the global cannabis supply chain,” he added (https://ibn.fm/5ncEY). Garayev will lend over 25 years of experience in finance, having served in various financial leadership roles in Amazon, Boeing BP, and RPK Capital. He is well versed in supporting successful organizations through developing and implementing accounting and reporting policies and building high-performance finance teams. Mr. Garayev adds to a growing list of competent, experienced, and capable individuals ready to take on the challenges ahead and elevate Flora Growth to another level of performance. These individuals are set to increase the overall productivity of the company’s workforce, allowing Flora to build a design-led collective of plant-based wellness and lifestyle brands that offers the world’s most compelling customer experience. For more information, visit the company’s website at www.FloraGrowth.com. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• Goldman Sachs’s yearly report on the global music industry expects music streaming revenues to reach $89.3 billion in 2030, with paid streaming contributing $55.6 billion and ad-funded streaming contributing $33.7 billion of the total
• Friendable’s 360-degree artist platform offers independent music artists the tools they need to produce, distribute, and market their music while generating (and keeping) revenue
• On average, artists lose 90% of streaming revenue to record labels, 10% to booking agents, and 15-20% of overall income to managers while feeling unsupported and controlled by these labels

The highly coveted yearly music industry update released by Goldman Sachs strives to answer the billion-dollar question – how much will the music industry be worth in 2030? The update suggests that global music streaming revenues will reach $89.3 billion in 2030, with paid streaming contributing $55.6 billion and ad-funded streaming contributing $33.7 billion. Goldman Sachs analyst Lisa Yang and a team of colleagues penned the company’s report citing that the reduced increase in its projection numbers is driven by higher paid streaming annual revenue per user and ad-funded streaming assumptions. The decrease also includes the decline in physical sales (https://ibn.fm/hbiqv). On average, artists lose 90% of streaming revenue to record labels, 10% to booking agents, and 15-20% of overall income to managers. The fees are not the only problem; most artists feel a lack of support and a lack of control, in addition to their financially burdensome strict financial contracts. In the changing landscape of the music industry, labels must be willing to adapt, and Friendable’s (OTC: FDBL) 360-degree streaming artist platform offers the solution for them to do that. Friendable is a mobile technology and marketing company focused on developing its Fan Pass Live artist platform and related-branded products. The 360-degree streaming artist platform is comprised of Fan Pass Live, Artist Republik, and FeaturedX – providing artists with everything they need to produce, distribute, and market their music without the contractual obligations placed on them by record labels. It provides opportunities for independent artists looking to find their footing in the industry and leverage the increase in the streaming industry. For artists, growth and other vital resources are locked behind walls of contracts and middlemen. There is no easy way to advance their careers without a solution that gives artists access to resources and elevates their careers. Partnering with the Fan Pass Live artist platform can give labels the tools they need to help advance artist careers. Artists have multiple advantages working with Fan Pass Live, Artist Republik, and FeaturedX platforms, including:

• Music distribution and management
• Music production assistance
• Press release and Instagram promotion
• Digital storefront activation
• Artist marketplace for collaborations
• Merchandise, logo, and promotional design support
• Virtual concert booking and ticketing mobile streaming service
• Live streaming support
• Revenue from fan tips, monthly artist contests, merchandise, and ticket sales
• Access to fan data and performance analytics
• Artist contests
• NFT Development and Metaverse performances – coming soon

In the future, Friendable will add NFT development and Metaverse performances to the artist offering. With NFTs changing the way we understand digital ownership and commerce, the company will use non-fungible tokens as a means for creators to generate additional revenue through the sales and distribution of their music. These NFTs will provide artists with an additional offering that can be traded or sold to fans, collectors, and music enthusiasts. Through Friendable’s Fan Pass Live artist platform, independent artists are gaining a distinctive advantage and entry into the streaming industry, not controlled by contracts or labels. The platform is built by artists, for artists. As a one-stop shop, Fan Pass Live and its branded assets provide a singular platform for artists to grow their audience, interact with fans, promote music, showcase work, sell merchandise, and generate revenue. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• Medical costs for concussions total $20 billion in the United States, a need for which there is no FDA-approved treatment
• The CDC estimates that more than 50% of people suffering a traumatic brain injury become moderately or severely disabled and have shorter life spans
• Odyssey provides a portfolio of diverse technologies and related medical products to meet the unmet medical needs of concussion and TBI patients

Each year, medical costs in the United States for concussions total $20 billion ($400 billion worldwide). There is a significant unmet medical need for treatments for concussions in the medical landscape, with most diagnosed patients sent home with a standard of care involving rest, analgesics for headaches, and anti-depressants. Repeat concussions can lead to early dementia and Chronic Traumatic Encephalopathy (“CTE”), with the likelihood of athlete head injury recurrence totaling 75% (https://ibn.fm/z6bKU). Currently, there is no FDA-approved drug treatment for concussions, with the CDC noting that about 50% of people with traumatic brain injury (“TBI”) will experience decline in their daily lives or die within five years of their injury, while 57% will become moderately or severely disabled (https://ibn.fm/f5dvW). Odyssey Health (OTC: ODYY), a medical technology company focused on lifesaving medical products that offer technological and clinical advantages over current standards of care, is moving forward in its quest to meet the unmet needs of concussion patients. Recently, the company announced that its investigational agent PRV-002, a fully synthetic, nonnaturally occurring neurosteroid intended to treat concussion, was reported to be safe and well tolerated in a small cohort of volunteers. The company is currently in the process of selecting clinical sites and developing the Investigator’s Brochure for a Phase 2 trial (https://ibn.fm/e0DMX). Odyssey provides a portfolio of diverse technologies, featuring four unique medical products currently in development. The company aims to deliver superior products with enhanced clinical utility and market potential. Beyond concussion treatment, Odyssey plans to develop treatments of related brain injury and neuropsychiatric disorders with other novel neurosteroids within its portfolio. These indications include major depressive disorder, post-traumatic stress disorder (“PTSD”), dementia, generalized anxiety, addiction, amyotrophic lateral sclerosis (ALS – Lou Gehrig’s Disease), and CTE. The company’s advisory boards play a vital role in developing novel treatments for unmet medical needs. The Scientific Advisory Board consists of James P. Kelly, MA, MD, FAAN, the Executive Director of the Marcus Institute for Brain Health (“MIBH”), and Professor of Neurology at the University of Colorado Anschutz Medical Campus. In addition to Dr. Kelly, the board includes Dallas C. Hack, MD, MPH, FACMPH, COL, US Army. Dr. Hack is also a Brain Health Consultant working with the NCAA, DoD, and Cohen Veterans Bioscience. In March 2022, Odyssey announced the formation of its Military Advisory Board, which supports Odyssey’s outreach efforts to the U.S. Military regarding funding and clinical sites for the treatment of TBIs. The board consists of current and veteran members of the armed forces, including James “Jim” Linder, Francis “Fran” Beaudette, Paul Toolan, and Tim Szymanski. The Sports Advisory Board was formed in March 2021 to support the company’s outreach efforts to enhance public awareness of TBIs and concussions, as well as the need for an FDA-approved therapy. The board consists of Steve “Mooch” Mariucci, Kurt Warner, Brett Favre, Abby Wambach, Mark Rypien, and David Ross. Through its Advisory Boards and Board of Directors, Odyssey is backed by decades of combined experience to further its objectives to meet the needs of patients who are currently without FDA-approved therapies in indications like concussion and TBIs. As demonstrated in its most recent trial, Odyssey’s device and treatment for concussions, Dr. Hack noted, “The overall low levels of PRV-002 in the blood support the hypothesis that more drug is getting to the brain itself when administered with the intranasal device. If this turns out to be the case, not only can the targeted effects of the drug be more efficacious, but the drug will also likely have fewer potential side effects.” Through this evidentiary analysis, the company is working to commence Phase 2 in the future. For more information, visit the company’s website at www.OdysseyHealthInc.com. NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

• FingerMotion launched its mobile device protection service on July 15, 2022, banking on the transition to and the proliferation of 5G within the Chinese market
• With the Chinese government targeting over 2 million 5G base stations by the end of the 2022 calendar year, FingerMotion is counting on consumers’ switch from 3G and 4G phones to 5G to grow its new product and market share as a whole
• Martin Shen, FingerMotion’s CEO, is confident that this new direction by the company will not only sustain but also supersede the previous years’ performance, having posted a 12% gross margin growth in 2022, up from 9% in the 2021 financial year
• He has reiterated that the company’s current revenue is “just the tip of the iceberg” and is confident that over the next 6-12 months, FingerMotion will achieve significant revenue growth

FingerMotion’s (NASDAQ: FNGR) latest offering, mobile device protection, launched on July 15, 2022, could not have come at a more opportune time. Mimicking Apple’s AppleCare service but specifically tailored for the Chinese market, FingerMotion sought to capitalize on a largely untapped market, previously limited to broken screen protection (https://ibn.fm/JIZUn). FingerMotion, an evolving technology company with a core competency in mobile payment and recharge platform solutions, has always kept its ear on the ground and has never shied away from exploring new sectors to grow its market share and create value for its shareholders. This outlook has yielded four key offerings: telecommunications products and services, SMS and MMS services, big data insights, and Rich Communication Services (“RCS”). Its latest addition acknowledges the changing consumer behavior and preferences, with many Chinese consumers switching up their older phones for newer ones, specifically those with 5G functionality. “Now with the massive onset of 5G phones, there’s a really large market in China that’s looking to change up their phones for, let’s say, 3G and 4G phones to 5G,” noted Martin Shen, the Chief Executive Officer (“CEO”) of FingerMotion (https://ibn.fm/YDOMc). FingerMotion is looking to bank on this transition and the proliferation of 5G to grow its new product. It believes that in doing so, it will grow its customer numbers and, more importantly, its gross margins, a key objective for the 2023 financial year. In a report published by Open Gov Asia, China is targeting over 2 million 5G base stations by the end of the 2022 calendar year. So far, the country has already launched over 1.4 million base stations serving over 500 million users. The goal for the Chinese government is to have 26 5G base stations for every 10,000 people by the end of 2025, up from five base stations for every 10,000 people in 2020 (https://ibn.fm/E7LpM). With over $900 billion in value added to the Chinese economy by mobile technologies and services, representing 5.6% of the country’s Gross Domestic Product (“GDP”), one would understand why the government is aggressively pushing for 5G infrastructure deployment. Most notably, this move to have 5G accessible to its citizens saw 285 million additional 5G connections in 2021 alone. For a nation where over 1 billion people use mobile internet services, FingerMotion recognizes a tremendous market opportunity for its new product (https://ibn.fm/jXa60). Mr. Shen is confident that this new direction by the company will be integral to sustaining the previous years’ performance and superseding it. Gross margins growth in the 2022 financial year was 12%, with 2021 posting a 9% growth and is hopeful that over the next 6-12 months, FingerMotion will achieve significant revenue growth. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• Consensus among autonomous vehicle experts increasingly lean in favor of implementing lidar solutions to promote AV safety
• HD cameras only provide raw image data in 2D; lidar uses laser technology to determine exact distance and location of objects
• Cepton produces state-of-the-art, intelligent, lidar-based applications for AV, ADAS, smart cities, connected spaces, and smart industrial applications
• CPTN engaged with top 10 global automotive OEMs, including GM and Ford

Expert opinions concerning autonomous vehicle (“AV”) safety are leaning in favor of using lidar (light detection and ranging) technologies in addition to HD cameras, a positive development for Cepton (NASDAQ: CPTN), a developer of lidar-based solutions that help enable Advanced Driver Assistance Systems (“ADAS”), AVs, smart cities, connected spaces, and smart industrial applications. The safety of AVs and ADAS hinges on the ability of the vehicle’s system to sense surrounding objects. Both HD cameras and lidar have their benefits and drawbacks; however, lidar is coming out ahead as the technology advances and costs come down. Industry experts like Volkswagen CEO Herbert Diess confirm the growing consensus that lidar is an essential solution (https://ibn.fm/QcNxs). According to Diess, Level 3 driving automation is safer with lidar because it offers redundant perception to 360-degree camera systems. Unlike HD cameras that only provide raw image data in 2D, lidar uses laser technology to determine an object’s exact distance and location. With this ability to detect large and small items at various distances, lidar systems can assign varying importance to objects depending on their proximity and size. Cepton produces state-of-the-art, intelligent, lidar-based applications for AV, ADAS, and other markets, including solutions for smart cities, connected spaces, and smart industrial applications. CPTN’s technology enables seamless high-volume manufacturing in partnership with leading Tier-1s. Cepton is leading the way in scaling up lidar for mass-market deployments. In addition to its significant ADAS lidar series production award with Koito on the General Motors business, Cepton has expanded its lidar use cases across smart infrastructure. “We thought ADAS in the near future would be the biggest market for lidar, and that’s why we focused all of our company efforts – whether it’s in technology invention or commercial development – into the ADAS industry,” said CPTN CEO and lidar pioneer Dr. Jun Pei in a recent interview with the Financial Times (https://ibn.fm/LRxu8). Cepton is also engaged with the other top 10 global automotive OEMs with the aim of making lidar a standard safety feature in all vehicles. For example, Ford Motor Company published an article last year stating that Ford had engaged with CPTN since 2016 for research and development collaboration and small-scale deployments (https://ibn.fm/cPvFO). Working with the team at Ford, Cepton delivered custom lidar solutions that helped enable R&D on advanced ADAS features. In addition, Ford also deployed Cepton’s lidars in some of their smart city projects. Cepton was established in 2016 by co-founders Dr. Jun Pei and Dr. Mark McCord. The company is headquartered in San Jose, California, with a presence in Germany, Canada, Japan, India, and China to serve a fast-growing customer base. With a dedicated team of researchers and scientists, Cepton aims to make its patented technology mainstream to enable scalable and intelligent 3D perception solutions across multiple major global markets. For more information, visit the company’s website at www.Cepton.com. NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

• Lexaria’s Mexican patent “Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Ingredients” joins the ranks of previously issued patents in Australia, India, Japan and the EU
• The patent allows the company to provide value in gaining regulatory approval for its DehydraTECH(TM)-enabled CBD for multiple indications in the health and wellness field
• Additional claims to Mexican patent #390001 include Alzheimer’s disease, Parkinson’s disease, schizophrenia, Human Immunodeficiency Virus (“HIV”) dementia, obesity, hepatic diseases, diabetes, appetite disorders, cancer chemotherapy, benign prostatic hypertrophy, irritable bowel syndrome, biliary diseases, ovarian disorders, marijuana abuse, and alcohol, opioid, nicotine, or cocaine addictions
• The global market of CBD for health and wellness purposes was valued at $4.9 billion in 2021 and is expected to grow to $47.22 billion by 2028

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced that the Company has received its 27th worldwide patent, granted in Mexico under registration #390001. The patent from Lexaria’s third patent family, “Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Agents,” has already been issued in Australia, India, and Japan (https://ibn.fm/3hANL). The patent applies to a range of active ingredients, including but not limited to non-psychoactive cannabinoids and NSAIDs in a wide variety of ready-to-drink consumer retail beverage products. Lexaria’s latest patent provides value to the company through its continued pursuit of gaining regulatory approval for its patented DehydraTECH(TM)-enabled cannabidiol (“CBD”) for the treatment of hypertension in regulated pharmaceutical applications. This has produced the claims necessary for the Mexico patent to use DehydraTECH-processed non-psychoactive cannabinoids to treat cardiac and cardiometabolic disorders. Additional claims granted to the Mexican patent #390001 include the treatment of neurological diseases, including Alzheimer’s disease, Parkinson’s disease, schizophrenia, and Human Immunodeficiency Virus (“HIV”) dementia. The indications also include obesity, hepatic diseases, diabetes, appetite disorders, cancer chemotherapy, benign prostatic hypertrophy, irritable bowel syndrome, biliary diseases, ovarian disorders, marijuana abuse, and alcohol, opioid, nicotine, or cocaine addictions. Lexaria’s DehydraTECH(TM) technology improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. The technology promotes fast-acting, less expensive, and more effective drug delivery and has been thoroughly evaluated through vivo, in vitro, and human clinical testing. Major benefits of the technology include:

• Increased drug delivery times in which patients feel the effects in a matter of minutes
• Increased bioavailability through the bloodstream
• Increased brain absorption as demonstrated through animal testing with higher drug quantities being delivered across the blood-brain barrier
• Improved drug potency with more of the drug ingested and made available to the body with lower dosing required to achieve maximum results
• Reduction in drug administration costs due to the reduced amount needing to be delivered
• Masking unwanted tastes which reduces the need for unnecessary sweeteners

The global demand for CBD for health and wellness purposes is high, with the worldwide market being valued at $4.9 billion in 2021 and expected to grow at a CAGR of 21.3% from 2022 to 2028, resulting in a value of $47.22 billion by 2028. The rise in demand can be attributed to the increased acceptance and use of CBD for wellness purposes and government approvals (https://ibn.fm/SFw2S). With the approval of its 27th patent, the company is still working on expanding the indications and efficacy of its DehydraTECH(TM) technology – with ~50 pending patents worldwide. The company’s pursuit has allowed it to leverage additional industries, including the need to fill a deficit in the hypertension market. On average, hypertension costs the country $131 billion annually, with more than 670,000 deaths in the United States attributed to hypertension as a primary or contributing factor in 2020. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX